Pàgina inicial > Resultats de la cerca: Gribben, John G.
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 4 registres trobats en 0.01 segons.
Articles, 4 registres trobats
Articles 4 registres trobats  
1.
9 p, 1.3 MB Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia : A cross-trial comparison of phase 3 studies / Robak, Tadeusz (Medical University of Lodz) ; Burger, Jan A. (The University of Texas MD Anderson Cancer Center) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Barr, Paul M. (University of Rochester Cancer Center) ; Owen, Carolyn (University of Calgary) ; Bairey, Osnat (Tel Aviv University) ; Hillmen, Peter (St. James's Institute of Oncology) ; Simpson, David (North Shore Hospital) ; Grosicki, Sebastian (Silesian Medical University) ; Devereux, Stephen (King's College Hospital NHS Foundation Trust) ; McCarthy, Helen (Royal Bournemouth Hospital) ; Coutre, Steven E (Stanford University School of Medicine) ; Quach, Hang (St. Vincent's Hospital) ; Gaidano, Gianluca (Amedeo Avogadro University of Eastern Piedmont) ; Maslyak, Zvenyslava (Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine) ; Stevens, Don A. (Norton Cancer Institute) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Gill, Devinder S. (Princess Alexandra Hospital) ; Flinn, Ian W. (Sarah Cannon Research Institute/Tennessee Oncology) ; Gribben, John G. (Queen Mary University of London) ; Mokatrin, Ahmad (Pharmacyclics LLC. an AbbVie Company) ; Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ; Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ; James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ; Kipps, Thomas J (University of California San Diego) ; Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ; Universitat Autònoma de Barcelona
Chemoimmunotherapy (CIT) and targeted therapy with single-agent ibrutinib are both recommended first-line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. [...]
2018 - 10.1002/ajh.25259
American Journal of Hematology, Vol. 93 Núm. 11 (november 2018) , p. 1402-1410  
Registre complet - Creative Commons
2.
13 p, 1.6 MB First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab : final analysis of the randomized, phase III iLLUMINATE trial / Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Greil, Richard (Salzburg Cancer Research Institute-CCCIT (Àustria)) ; Demirkan, Fatih (Dokuz Eylul University (Turquía)) ; Tedeschi, Alessandra (Niguarda Ca Granda Hospital (Itàlia)) ; Anz, Bertrand (Tennessee Oncology (Estats Units)) ; Larratt, Loree (University of Alberta Hospital (Canadà)) ; Simkovic, Martin (University Hospital and Medical School Hradec (Txèquia)) ; Novak, Jan (Charles University (Txèquia)) ; Strugov, Vladimir (Almazov National Medical Research Centre (Rússia)) ; Gill, Devinder (Princess Alexandra Hospital) ; Gribben, John G. (Barts Cancer Institute) ; Kwei, Kevin (Pharmacyclics LLC) ; Dai, Sandra (Pharmacyclics LLC) ; Hsu, Emily (Pharmacyclics LLC) ; Dean, James P. (Pharmacyclics LLC) ; Flinn, Ian W. (Sarah Cannon Research Institute) ; Universitat Autònoma de Barcelona
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. [...]
2022 - 10.3324/haematol.2021.279012
Haematologica, Vol. 107 (january 2022) , p. 2108-2120  
Registre complet - Creative Commons
3.
15 p, 1.3 MB Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population : diagnostic and prognostic implications / Baptista, Maria Joao (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Tapia, Gustavo (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Muñoz-Marmol, Ana Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Muncunill Farreny, Josep (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; García, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Montoto, Silvia (Centre for Haemato-Oncology. Barts Cancer Institute. Queen Mary University of London) ; Gribben, John G. (Centre for Haemato-Oncology. Barts Cancer Institute. Queen Mary University of London) ; Calaminici, Maria (Centre for Haemato-Oncology. Barts Cancer Institute. Queen Mary University of London) ; Martinez, Antonio (Hospital Clínic i Provincial de Barcelona) ; Veloza, Luis (Hospital Clínic i Provincial de Barcelona) ; Martínez-Trillos, Alejandra (Hospital Clínic i Provincial de Barcelona) ; Aldámiz-Echevarría, T (Hospital General Universitario Gregorio Marañón) ; Menarguez, Javier (Hospital General Universitario Gregorio Marañón) ; Terol, Maria José (Hospital Clínic Universitari (València)) ; Ferrandez, Antonio (Hospital Clínic Universitari (València)) ; Alcoceba, Miguel (Hospital Universitario de Salamanca) ; Briones Meijide, Javier (Institut d'Investigació Biomèdica Sant Pau) ; Gonzalez-Barca, Eva (Hospital Duran i Reynals (Hospitalet del Llobregat)) ; Climent, Fina (Institut d'Investigació Biomèdica de Bellvitge) ; Muntañola, Ana (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Moraleda, José Maria (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ; Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Abrisqueta, Pau (Hospital Universitari Vall d'Hebron) ; Abella Monreal, Eugenia (Hospital del Mar (Barcelona, Catalunya)) ; Colomo, Luis (Hospital del Mar (Barcelona, Catalunya)) ; García-Ballesteros, Carlos (Hospital Arnau de Vilanova (València)) ; Garcia-Caro, Montserrat (Hospital de Mataró. Consorci Sanitari del Maresme) ; Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Ribera, José Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Mate Sanz, Jose Luís (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Navarro, José-Tomás (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
The frequency of aggressive subtypes of B-cell non-Hodgkin lymphoma (B-NHL), such as high-grade B-cell lymphomas (HGBL) with MYC and BCL2 and/or BCL6 rearrangement (HGBL-DH/TH) or Burkitt-like lymphoma (BL) with 11q aberration, is not well known in the HIV setting. [...]
2022 - 10.1111/his.14798
Histopathology, 2022  
Registre complet -
4.
10 p, 631.8 KB Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL : analysis from the iLLUMINATE study / Greil, Richard (Salzburg Cancer Research Institute-CCCIT, Cancer Cluster Salzburg. IIIrd Medical Department Paracelsus Medical University) ; Tedeschi, Alessandra (Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Anz, Bertrand (Tennessee Oncology. Department of Medical Oncology) ; Larratt, Loree (University of Alberta Hospital. Department of Clinical Hematology) ; Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ; Gill, Devinder (Princess Alexandra Hospital. Department of Clinical Hematology) ; Gribben, John G. (Queen Mary University of London, Barts Cancer Institute. Centre for Haemato-Oncology) ; Flinn, Ian W. (Sarah Cannon Research Institute/Tennessee Oncology) ; Wang, Zhengyuan (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Cheung, Leo W. K. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Nguyen, Aaron N. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company. Biostatistics) ; Styles, Lori (Pharmacyclics LLC, an AbbVie Company. Clinical Science) ; Demirkan, Fatih (Dokuz Eylül University. Department of Hematology) ; Universitat Autònoma de Barcelona
The online version contains supplementary material available at 10. 1007/s00277-021-04536-6.
2021 - 10.1007/s00277-021-04536-6
Annals of Hematology, Vol. 100 (may 2021) , p. 1733-1742  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
2 Gribben, J.
1 Gribben, John
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem